OX40-OX40L Interaction Promotes Proliferation and Activation of Lymphocytes via NFATc1 in ApoE-Deficient Mice

Jinchuan Yan*, Hongling Su, Liangjie Xu, Cuiping Wang
Department of Cardiology, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China

Abstract

Background: Our previous studies have shown that OX40-OX40L interaction regulates the expression of nuclear factor of activated T cells c1 (NFATc1) in ApoE−/− mice during atherogenesis. The aim of this study was to investigate whether OX40-OX40L interaction promotes Th cell activation via NFATc1 in ApoE−/− mice.

Methods and Results: The lymphocytes isolated from spleen of ApoE−/− mice were cultured with anti-CD3 mAb in the presence or absence of anti-OX40 or anti-OX40L antibodies. The expression of NFATc1 mRNA and protein in isolated lymphocytes were measured by real time PCR (RT-PCR) and flow cytometry (FCM), respectively. The proliferation of lymphocytes was analyzed by MTT method, and the expression of IL-2, IL-4 and IFN-γ in the cultured cells and supernatant were measured by RT-PCR and enzyme-linked immunosorbent assay (ELISA), respectively. After stimulating OX40-OX40L signal pathway, the expression of NFATc1 and the proliferation of leukocytes were significantly increased. Anti-OX40L suppressed the expression of NFATc1 in lymphocytes of ApoE−/− mice. Anti-OX40L or the NFATc1 inhibitor (CsA) markedly suppressed the cell proliferation induced by anti-OX40. Moreover, the expression of IL-2 and IFN-γ was increased in lymphocytes induced by OX40-OX40L interaction. Blocking OX40-OX40L interaction or NFATc1 down-regulated the expression of IL-2 and IFN-γ, but didn’t alter the expression of IL-4 in supernatants.

Conclusion: These results suggest that OX40-OX40L interaction promotes the proliferation and activation of lymphocytes through NFATc1.

Introduction

Atherosclerosis is a chronic-inflammatory disease in the context of hypercholesterolemia, in which both innate and adaptive immune responses play a role [1,2]. TNF receptor pathway can provide co-stimulatory signals and has been implicated in the onset and progression of atherosclerosis and ACS (acute coronary syndromes). Previous studies from our laboratory and others have shown an emerging role of OX40-OX40L interaction in the development of atherosclerotic lesions during atherogenesis [3]. OX40-OX40L interaction regulates the expression of nuclear factor of activated T cells c1 (NFATc1) in ApoE−/− mice [11]. Based on our previous findings and others’ reports, we proposed that NFATc1 was a downstream mediator of OX40-OX40L interaction during atherogenesis.
OX40-OX40L Interaction Activates Lymphocytes

A whole range of identified cytokines have been shown to play a role in atherogenesis, some with pro-atherogenic properties while others having anti-atherogenic properties. Th cells present in the atherosclerotic lesions showed properties of Th1 phenotype with increased levels of IL-2 and IFN-γ, whereas the Th2 cytokines IL-4 was found in modest quantities [12]. NFAT transcription factors have various implications on many cytokines, such as IL-2, IL-4 and IFN-γ, which are highly associated with NFAT. However, the precise mechanism by which OX40-OX40L interaction target NFATc1 in ApoE−/− mice during atherogenesis remains unclear. Hence, we investigated whether and how OX40-OX40L interaction regulated Th1 cell proliferation and viability through NFATc1 in ApoE−/− mice.

Methods

Mice

Male apoE−/− mice on a C57BL/6J background, obtained from the Jackson Laboratory, USA, were housed on a 12 h light-dark cycle in a specific pathogen-free environment with free access to rodent chow and water. All procedures were conducted according to the National Ethics Committee for Care and Use of Laboratory Animals for Research of the Medical School. At 6 weeks of age, the mice were divided into the following groups: control group (sham-operation group) (n = 10), model group (n = 10), OX40/OX40L activated group (n = 10) and OX40/OX40L inhibited group (n = 10). The latter three groups were fed a Western type diet containing 0.25% cholesterol and 15% cocoa butter and a constrictive collar was placed around right carotid arteries of these mice for 4 weeks to induce plaques formation.

Atherosclerotic Plaques Measured by HE Staining

Atherosclerotic plaque sections from the carotid artery (5 μm) were stained with hematoxylin and eosin.

Cell Culture

24-well plates were coated overnight with anti-CD3 antibody (10 μg/ml; PharMingen, San Diego, CA) at 4°C. Unbound Ab was removed by washing before the addition of cells. 6 weeks old male ApoE−/− mice were killed, and their spleen were removed. Cell suspensions were made by crushing the tissues between gauze. After separation with Ficoll-paque (Amersham Pharmacia Biotech, Herts, UK), the cell suspensions were cultured in 24-well plates at an initial density of 1×106 cells per well. For CD3/OX40 costimulation, cells were cultured with agonistic anti-OX40 mAb (20 μg/ml) in the presence or absence of cyclosporine A (CsA) (A pharmacological inhibitor of the calcineurin-NFAT activation pathway). For soluble blockade using anti-OX40L mAb, cells were cultured with anti-OX40L mAb or inactivated anti-OX40L mAb (20 μg/ml) with anti-OX40 mAb (20 μg/ml). For MTT, cell cultures were harvested without re-stimulation after 24, 48 and 72 h. For flow cytometric analyses, ELISA and real-time PCR, cell cultures were harvested after 72 h.

The Cell Proliferation Detected by MTT

Lymphocytes were incubate without re-stimulation after 24, 48 and 72 h, MTT was added at a final concentration of 5 mg/ml, and incubation was continued for a further 4 h. After 4 h, DMSO was added, and following mixing, colorimetric determination of MTT reduction was made at 490 nm.

Real-Time PCR

Total RNA was isolated from spleen using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. The RNA was quantified, and reverse-transcribed (RevertAid M-MuLV reverse transcriptase) according to manufacturer’s protocol. Quantitative gene expression analysis was performed on an ABI PRISM 7700 (Applied Biosystems, Foster City, Calif) using SYBR Green technology. PCR thermal cycling conditions were 95°C for 30 sec, and 40 cycles of 95°C for 5 and 60°C for 20 sec in a total volume of 20 μl/reaction. Transcript levels of target genes were calculated according to the 2−ddCt method as supplied by the manufacturer (ABI PRISM 7700 user bulletin PE Applied Biosystems) and expressed in arbitrary units. The primers used are as follows: mouse NFATc1 primers: forward, 5′-GTTGCAAGCAGCATCAACGGCCT-3′ and reverse, 5′-TA CGAGGGCCTGTGGGACCGA-3′; mouse IL-4 primers: forward, 5′-TGGCATCCGATGACCCGATT-3′ and reverse, 5′-TAAAACGCTGACGCTATCTC-3′; mouse IL-4 primers: 5′-TCGGCGATTGGACGAGGTC-3′ and reverse, 5′-GA AAGAGCGGAAAAGAGGTC-3′; mouse INF-γ primers: 5′-CGCTACACACTGCATCTGGG-3′ and reverse: 5′-TGAGCTCTTTGAATGCTTGG-3′; mouse IL-2 primers: 5′-TGCTGCTTGGTCAACAGGC-3′ and reverse: 5′-GAGCCCTATGTTGGTGACG-3′.

Abs and Flow Cytometry

Control rat IgG (Cappel), and anti-CD3ε (2C11) were used for cell culture. Agonistic anti-mouse OX40 mAb (OX86) and inhibitory anti-OX40L mAb (RM134L) were used to stimulate and inhibit OX40 signals, respectively.

Figure 1. HE-stained cross sections of carotid 6 weeks in ApoE−/− mice injecting with anti-OX40(100 μg/ml) and anti-OX40L(100 μg/ml) 2 times a week. Representative of plaques in control(C) and treated with anti-OX40(A) and anti-OX40L(B) stained with HE.

doi:10.1371/journal.pone.0060854.g001
For evaluation of NFATc1 expression, lymphocytes were first stained with PE- anti-CD4, then 1× permeabilizing solution (500 µL, Becton Dickinson) was added and incubated for 1.5 h at 4°C in the dark. After washing with 1 mL buffer, lymphocytes were stained with purified anti-NFATc1/7A6, santa cruz) followed by FITC–anti-mouse IgG (Sigma-Aldrich). Flow cytometry data were acquired on a FACS Calibur (BD Biosciences) and analyzed with Flow Jo software (Version 8.5.2; TreeStar).

ELISA
Cultured supernatants were assessed for IL-2, IL-4 and IFN-γ cytokine content by enhanced sandwich ELISA protocols(e-Bioscience, Belgium).

Statistical Analysis
Data were expressed as means ± SD and analyzed by SPSS 13.0 software. For comparisons between two variables, the unpaired Student’s t test was used. Comparisons among more than two groups involved one-way analysis of variance (ANOVA) followed by Post Hoc LSD test. A two-tailed P<0.05 was considered statistically significant.

Results

Effects on the Atherosclerotic Plaques Area and Histological Aspects
As shown in Fig. 1, HE staining revealed that the structures of carotid artery were different in ApoE−/− mice. The model mice were injected with anti-OX40 (100 µg/ml) and anti-OX40L (100 µg/ml) 2 times a week for 6 weeks, respectively. The plaques surface area was significantly increased in anti-OX40 treated group (Fig. 1A) compared with control group (Fig. 1C). Contrary, plaques in anti-OX40L treated group (Fig. 1B) were markedly decreased when compared with control and anti-OX40 treated group.

OX40-OX40L Interaction and NFATc1 are Required for the Proliferation of Lymphocytes
The effect of OX40-OX40L interaction on cell proliferation was measured using the MTT assay. First, lymphocytes were treated with a range of anti-OX40 (10, 20, and 40 µg/ml) and were harvested at 24 h, 48 h and 72 h. Anti-OX40 promoted proliferation of lymphocytes in time-dependent manner, reached maximum at 48 h, with maximal effect occurring at 20 µg/ml (Fig. 2), and the proliferation of lymphocytes didn’t show been promoted more effectively when were cultured with anti-OX40 (40 µg/ml) or harvested at 72 h.
In pretreatment with anti-OX40L (20, 80, 100 and 120 μg/ml) for 10 min, the proliferation of lymphocytes induced by anti-OX40 is markedly suppressed, with maximal effect occurring at 100 μg/ml and 48 h (Fig. 3).

Lymphocytes were treated with anti-OX40 (20 μg/ml), anti-OX40L (100 μg/ml) and inactivated anti-OX40L (100 μg/ml) respectively, at the maximal effect time (48 h), the proliferation of lymphocytes was markedly increased after anti-OX40-stimulated. Whereas down regulated after inhibited OX40-OX40L interaction, there was no difference between with or without inactivated anti-OX40L (Fig. 4). Anti-OX40L (20 μg/ml) or CsA (100 ng/ml) can significantly suppressed OX40-induced proliferation of lymphocytes (Fig. 5).

OX40-OX40L Interaction on the Expression of NFATc1 in Lymphocytes

After cultured with anti-OX40 in the presence or absence of inactivated anti-OX40L, the expression of mRNA and protein of NFATc1 in lymphocytes is substantially up-regulation. In pretreatment with anti-OX40L/100 μg/ml for 10 min, the expression of NFATc1 induced by anti-OX40 is markedly down-regulation (Fig. 6A, B).

OX40-OX40L Interaction Controls Th Cell Activation through NFATc1 in Lymphocytes

The expression of IL-2 and IFN-γ, in the cell and supernatants, was significantly increased when incubated with anti-OX40 in the presence or absence of inactivated anti-OX40L. A large decrease after anti-OX40-stimulated in the presence of anti-OX40L or CsA, but the level of IL-2 and IFN-γ was still more than that of treatment with anti-CD3 alone. However, for the same treatment, the expression of IL-4 in the cells and supernatants remained substantially unchanged (Fig. 7A, B).

The Characteristics of Lymphocytes (Th)

We analyzed the lymphocytes with FACS during with or without anti-OX40-stimulated. As show in the Fig. 8, R2 were CD4+ lymphocytes (A). Th1 cells were labeled with IFNγ CD4+ lymphocytes. Th2 cells were labeled with IL-4 CD4+ lymphocytes. The proportion of Th1 cells were more than Th2 cells in the lymphocytes isolated from spleen of ApoE−/− mice (B). When lymphocytes were stimulated with anti-OX40, Th1 cells were significantly increased in lymphocytes (from 8.6% to 17.4%, C).

Discussion

In our previous study, we found the OX40/OX40L interaction regulated the expression of NFATc1 in ApoE−/− mice and promoted the intracellular signal transduction pathways [10–11].
OX40-OX40L is a pair of type II membrane glycoprotein with homology to the tumor necrosis factor family. OX40-OX40L interaction not only plays an important role in immune responses, but also may contribute to promotion of lymphocytes activation in the process of atherosclerosis.

Based on our previous researches, we investigated whether OX40-OX40L interaction regulated lymphocytes proliferation and viability through NFATc1 in ApoE^{-/-} mice. In this study, when stimulating OX40-OX40L interaction, the plaques surface area and proliferation of lymphocytes was significantly increased. Blocking OX40-OX40L interaction or using inhibitor of

Figure 6. The expression of NFATc1 in lymphocytes by Real-Time PCR (A) and FCM (B). **, *** represent p<0.01 and p<0.001, respectively.
doi:10.1371/journal.pone.0060854.g006
Figure 7. The levels of IL-2, IFN-γ and IL-4 induced by OX40-OX40L interaction in lymphocytes. *p<0.05, **p<0.01, ***p<0.001, ns p>0.05, respectively.
doi:10.1371/journal.pone.0060854.g007

Figure 8. R2 were CD4+ lymphocytes (A). Th1 cells were labeled with IFNγ CD4+ lymphocytes. Th2 cells were labeled with IL-4 CD4+ lymphocytes. The proportion of Th1 and Th2 cells in the lymphocytes isolated from spleen of ApoE−/− mice(B). When lymphocytes were stimulated with anti-OX40, Th1 cells were significantly increased in lymphocytes(C).
doi:10.1371/journal.pone.0060854.g008
NTATc1(CsA), we found the similarly suppressed effect of the cells proliferation and plaques surface area. These data suggested that OX40-OX40L and NFATc1 may be act a critical role in the proliferation of lymphocytes and atherosclerotic plaques.

Most of the T lymphocytes present in the atherosclerotic plaques both in humans as well as in animal models were seen to be CD4⁺ T cells. These CD4 bearing Th cells have a central regulatory role in immune and autoimmune responses and are further classified mainly into Th1 subtype and Th2 subtype according to the cytokines they secrete. Studies in experimental models show a pro-atherogenic role for Th1 cells and an anti-atherogenic role for Th2 cells [13–14]. OX40-OX40L interaction has been linked to both Th1 and Th2 activation in several disease models [15–24]. We determined the capability of lymphocytes to produce Th1(IFN-γ,IL-2) and Th2 (IL-4) cytokines.

Our previous data shows that the OX40-OX40L interaction is transmitted through increasing the level of NFATc1 that accumulates and/or persists in the nucleus [11]. In this study, stimulating OX40-OX40L interaction, the expression of IL-2 and IFN-γ was significantly increased in cultured lymphocytes. While blocking the OX40-OX40L interaction or using inhibitor of NFATc1, we can see the similarly down-regulated effect on the expression of IL-2 and IFN-γ. However, the expression of IL-4 in supernatants remained substantially unchanged. Further analyzed with FACS, Th1 cells were significantly increased in lymphocytes when stimulated with anti-OX40. These data supports the opinion that atherosclerosis is a Th1-mediated disease. However, to clarify the precise mechanisms for these observations, further studies will be required.

From above results, OX40-OX40L and/or its downstream signaling intermediates such as NFATc1 will likely prove to be excellent future therapeutic targets for atherosclerosis. It is intriguing to suggest that specific and early intervention directed at the interaction of OX40-OX40L and blockade of NFATc1 activation signaling might be a promising new approach to atherosclerotic disorders. They offer the advantage of a potentially selective immune-modulatory rather than harsh anti-inflammatory therapy, a strategy likely to be favourable in the context of atherosclerosis as a chronic inflammatory condition.

Author Contributions
Made critical revision of manuscript: JCY CPW LJX. Conceived and designed the experiments: JCY HLS LJX. Performed the experiments: HLS LJX. Analyzed the data: JCY CPW. Contributed reagents/materials/analysis tools: JCY HLS LJX. Wrote the paper: LJX HLS.

References
1. Gotman I, Sharpe AH, Lichtman AH (2008) T-cell costimulation and co-inhibition in atherosclerosis. Circ Res 103: 1270–1281.
2. Van Wauwrooj Fj, van Puijvelde GH, de Vos P, Yagita H, van Berkel TJ, et al. (2007) Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscl Thromb Vasc Biol 27: 204–210.
3. Liu DM, Yan JC, Wang CP, Chen GH, Ding S, et al. (2008) The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chinn Acta 397: 22–26.
4. Hogan PG, Chen L, Nardone J, Rao A (2003) Transcriptional regulation by calcineurin, calcium, and NFAT. Genes Dev 17: 2205–2212.
5. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, et al. (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807–817.
6. Clipstone NA, Crabtree GR (1992) Identification of calcineurin as a key signaling enzyme in T lymphocyte activation. Nature 357: 695–697.
7. Fruman DA, Klee CB, Bierer BE, Burakoff SJ (1992) Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci U S A 89: 3601–3605.
8. Sieber M, Baumgras S (2009) Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506. Cell Commun Signal 7: 25.
9. Karpurapu M, Wang D, Singh NK, Li Q, Rao GN (2008) NFATc1 targets cyclin A in the regulation of vascular smooth muscle cell proliferation during restenosis. J Biol Chem 283: 26577–26590.
10. Yan J, Wang C, Du R, Liu P, Chen G (2009) OX40-OX40L ligand interaction may activate phospholipase C signal transduction pathway in human umbilical vein endothelial cells. J Biol Chem 284: 460–464.
11. Xu L, Yan JC, Wang B, Liu PJ, Gong J, et al. (2011) Effect of the costimulatory molecules OX40-OX40L interaction on the expression of NFATc1 in leukocytes of apolipoprotein E-deficient mice. Zhonghua Xin Xue Guan Bing Za Zhi 39: 526–530.
12. Yoshitaka T, Nakajima A, Akiba H, Ishiwa T, Asano G, et al. (2000) Contribution of OX40/OX40L ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 30: 2815–2823.
13. Macian F (2005) NFAT protein: key regulators of T-cell development and function. Nat Rev Immunol 5: 472–484.
14. Huber SA, Sakken P, David C, Newell MK, Tracy RP (2001) T helper-cell phenotype regulates atherosclerosis in mice under conditions of hypercholesterolemia. Circulation 103: 2610–2616.
15. Laurat E, Poirier B, Tupin E, Caliguri G, Hansson GK, et al. (2001) In vivo downregulation of T helper cell 1 immune responses reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 104: 197–202.
16. Arendes RS, He H, Westlake RM, Chen Al, Sharpe AH, et al. (2002) Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur J Immunol 32: 2874–2980.
17. Healy AM, Izmailova E, Fitzgerald M, Walker R, Hattersley M, et al. (2006) PKCθ-betadeficient mice are protected from Th1-dependent antigen-induced arthritis. J Immunol 177: 1890–1893.
18. Akiba H, Miyahira Y, Atsumi T, Takenaka K, Nohara C, et al. (2000) Critical contribution of OX40 ligand to Th helper cell type 2 differentiation in experimental leish- maniasis. J Exp Med 191: 375–380.
19. Ishii N, Nojihou LC, Murata K, Sato T, Kamanaka M, et al. (2003) OX40 (CD134) and OX40 ligand interaction plays an adjuvant role during in vivo Th2 responses. Eur J Immunol 33: 2372–2381.
20. Ito T, Wang YH, Duramad O, Hori T, Delepesse GJ, et al. (2005) TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 202: 1213–1223.
21. Lane P (2000) Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th1) and Th2 cells. J Exp Med 191: 201–206.
22. al-Shamkhani A, Gubser D, Ehlert F, Sedlacek M, Ehlert F, et al. (1996) The sole receptor for the OX40 ligand. J Exp Med 180: 1460–1464.
23. Walker LS, Kulbertus-Judge A, Flynn S, Brocker T, Lane PJ (2000) Co-stimulation of CD4⁺ T cells by OX40L is required for the production of the cytokine IL-12. Eur J Immunol 30: 2815–2823.
24. Carboni S, Aboul-Enein F, Waltzinger C, Killeen N, Lassmann H, et al. (2000) Foreign antigen-specific T cells are required for OX40 ligation to induce interleukin-12 production. J Immunol 164: 2960–2966.

PLOS ONE | www.plosone.org 7 April 2013 | Volume 8 | Issue 4 | e60854